Effects of molsidomine and lexipafant in hepatic ischaemia-reperfusion injury

Injury

Volumn 35, Issue 3, 2004, Pages 232-237

  Aldemir, Mustafa ^a   Boşnak, Mehmet ^a   Al, Behçet ^a   Büyükbayram, Hüseyin ^a   Taçyildiz, Ibrahim ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Animal; Ischaemia reperfusion; Lexipafant; Liver; Male; Malondialdehyde; Microscopy; Molsidomine; Pringle manoeuvre; Rats; Score; Sprague Dawley; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASE; LEXIPAFANT; MALONALDEHYDE; MOLSIDOMINE; NITRIC OXIDE DONOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CARDIA; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; LIVER INJURY; LIVER ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TIME; TISSUE LEVEL;

EID: 1242270580     PISSN: 00201383     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-1383(03)00217-1     Document Type: Article

References (34)

1. Adamson G.M., Billings R.E. Cytokine toxicity and induction of NO synthase activity in cultured mouse hepatocytes. Toxicol Appl Pharmacol. 119:1993;100-107.
2. Clavien P.A., Harvey P.R., Strasberg S.M. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation. 53:1992;957-978.
3. Clavien P.A. Sinusoidal endothelial cell injury during hepatic preservation and reperfusion. Hepatology. 28:1998;281-285.
4. Darley-Usmar V., Wiseman H., Halliwell B. Nitric oxide and oxygen radicals: a question of balance. FEBS Lett. 369:1995;131-135.
5. Dunon D., Piali L., Imhof B.A. To stick or not to stick: the new leukocyte homing paradigm. Curr Opin Cell Biol. 8:1996;714-723.
6. Filep J., Herman F., Braquet P., Mozes T. Increased levels of platelet-activating factor in blood following intestinal ischaemia in the dog. Biochem Biophys Res Commun. 158:1989;353-359.
7. Formela L.J., Wood L.M., Whittaker M., Kingsnorth A.N. Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist. Br J Surg. 81:1994;1783-1785.
8. Geller D.A., Lowenstein C.J., Shapiro R.A., Nussler A.K., Di Silvio M., Wang S.C.et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA. 90:1993;3491-3495.
9. Geller D.A., Nussler A.K., Di Silvio M., Lowenstein C.J., Shapiro R.A., Wang S.C.et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci USA. 90:1993;522-526.
10. Gomez-Chiarri M., Ortiz A., Lerma J.L., Lopez-Armada M.J., Mampaso F., Gonzalez E.et al. Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. Lab Invest. 70:1994;449-459.
11. Harbrecht B.G., Billiar T.R., Stadler J., Demetris A.J., Ochoa J.B., Curran R.D.et al. Nitric oxide synthesis serves to reduce hepatic damage during acute murine endotoxemia. Crit Care Med. 20:1992;1568-1574.
12. Hughes H., Farhood A., Jaeschke H. Role of leukotriene B4 in the pathogenesis of hepatic ischaemia-reperfusion injury in the rat. Prostaglandins Leukot Essent Fatty Acids. 45:1992;113-119.
13. Jaeschke H. Cellular adhesion molecules: regulation and functional significance in the pathogenesis of liver diseases. Am J Physiol. 273:1997;G602-G611.
14. Kingsnorth A.N., Galloway S.W., Formela L.J. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 82:1995;1414-1420.
15. Kukovetz W.R., Holzmann S. Cyclic GMP as the mediator of molsidomine-induced vasodilatation. Eur J Pharmacol. 122:1986;103-109.
16. Kukovetz W.R., Holzmann S. Mechanism of vasodilation by molsidomine. Am Heart J. 109:1985;637-640.
17. Kumins N.H., Hunt J., Gamelli R.L., Filkins J.P. Molsidomine increases endotoxic survival and decreases cytokine production. Shock. 7:1997;200-205.
18. Lane J.S., Todd K.E., Gloor B., Chandler C.F., Kau A.W., Ashley S.W.et al. Platelet-activating factor antagonism reduces the systemic inflammatory response in a murine model of acute pancreatitis. J Surg Res. 99:2001;365-370.
19. Liu Q., Djuricin G., Rossi H., Bewsey K., Nathan C., Gattuso P.et al. The effect of lexipafant on bacterial translocation in acute necrotizing pancreatitis in rats. Am Surg. 65:1999;611-616.
20. Maier R.V., Hahnel G.B., Fletcher J.R. Platelet-activating factor augments tumor necrosis factor and procoagulant activity. J Surg Res. 52:1992;258-264.
21. Marubayashi S., Dohi K., Ochi K., Kawasaki T. Role of free radicals in ischemic rat liver cell injury: prevention of damage by alpha-tocopherol administration. Surgery. 99:1986;184-192.
22. Meenan J., Grool T.A., Hommes D.W., Dijkhuizen S., ten Kate F.J., Wood M.et al. Lexipafant (BB-882), a platelet-activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis. Eur J Gastroenterol Hepatol. 8:1996;569-573.
23. Nishida J., McCuskey R.S., McDonnell D., Fox E.S. Protective role of NO in hepatic microcirculatory dysfunction during endotoxemia. Am J Physiol. 267:1994;G1135-G1141.
24. Ontell S.J., Makowka L., Ove P., Starzl T.E. Improved hepatic function in the 24-hour preserved rat liver with UW-lactobionate solution and SRI 63-441. Gastroenterology. 95:1988;1617-1624.
25. Ontell S.J., Makowka L., Trager J., Mazzaferro V., Ove P., Starzl T.E. Pharmacologic modulation of experimental postischemic hepatic function. Ann Surg. 209:1989;200-210.
26. Pastor C.M., Losser M.R., Payen D. Nitric oxide donor prevents hepatic and systemic perfusion decrease induced by endotoxin in anesthetized rabbits. Hepatology. 22:1995;1547-1553.
27. Rangan U., Bulkley G.B. Prospects for treatment of free radical-mediated tissue injury. Br Med Bull. 49:1993;700-718.
28. Shibuya H., Ohkohchi N., Tsukamoto S., Satomi S. Tumor necrosis factor-induced, superoxide-mediated neutrophil accumulation in cold ischemic/reperfused rat liver. Hepatology. 26:1997;113-120.
29. Shiomi M., Wakabayashi Y., Sano T., Shinoda Y., Nimura Y., Ishimura Y.et al. Nitric oxide suppression reversibly attenuates mitochondrial dysfunction and cholestasis in endotoxemic rat liver. Hepatology. 27:1998;108-115.
30. Strasberg S.M., Howard T.K., Molmenti E.P., Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology. 20:1994;829-838.
31. Sun Z., Wang X., Deng X., Lasson A., Soltesz V., Borjesson A.et al. Beneficial effects of lexipafant, a PAF antagonist on gut barrier dysfunction caused by intestinal ischaemia and reperfusion in rats. Dig Surg. 17:2000;57-65.
32. Suzuki S., Toledo-Pereyra L.H. Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischaemia and reperfusion injury. J Surg Res. 57:1994;253-258.
33. Suzuki S., Toledo-Pereyra L.H., Rodriguez F.J., Cejalvo D. Neutrophil infiltration as an important factor in liver ischaemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation. 55:1993;1265-1272.
34. Szabo C., Wu C.C., Mitchell J.A., Gross S.S., Thiemermann C., Vane J.R. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res. 73:1993;991-999.